The European Medicines Agency has begun the process of relocating to their new headquarters located in Amsterdam. The EMA will leave its premises in London on the 1st March 2019. They will temporarily move over to the ‘Spark Building’ (Orlyplein 24, 1043 DP Amsterdam, The Netherlands). This temporary location will hold visits and meetings before they move into their future permanent location in Amsterdam Zuidas: (European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands).
From the 4th to the 8th of March, the EMA will operate on the basis of extended teleworking. During this week, only a small number of staff will be present with the remaining to follow the week after. To ensure the continuation of the main activities, the EMA has implemented phase 4 of its business continuity plan (BCP). The focus will be on the authorisation, maintenance and supervision of medicines, ongoing Brexit preparedness/ implementation activities and preparing for the implementation of the new veterinary legislation.
If you would like to discuss your specific requirements relating to Brexit readiness and how MIAS Pharma can help you, get in touch with us today at +353 (1) 846 3605 or email@example.com. In the meantime, you can check out the services we offer here.